Meniere's Disease News and Research RSS Feed - Meniere's Disease News and Research

Meniere's disease is an abnormality of the inner ear causing a host of symptoms, including vertigo or severe dizziness, tinnitus or a roaring sound in the ears, fluctuating hearing loss, and the sensation of pressure or pain in the affected ear. The disorder usually affects only one ear and is a common cause of hearing loss. Named after French physician Prosper Ménière who first described the syndrome in 1861.
First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease. [More]
Researchers may have figured out ways to attack Meniere's disease

Researchers may have figured out ways to attack Meniere's disease

Researchers at University of Colorado School of Medicine may have figured out what causes Meniere's disease and how to attack it. According to Carol Foster, MD, from the department of otolaryngology and Robert Breeze, MD, a neurosurgeon, there is a strong association between Meniere's disease and conditions involving temporary low blood flow in the brain such as migraine headaches. [More]

New study tests vestibular prosthesis to help restore balance for people with Meniere's disease

Many disorders of the inner hear which affect both hearing and balance can be hugely debilitating and are currently largely incurable. Cochlear implants have been used for many years to replace lost hearing resulting from inner ear damage. [More]
Study explores views, beliefs about triggers of Meniere's disease symptoms

Study explores views, beliefs about triggers of Meniere's disease symptoms

A report in one of the last issue of Psychotherapy and Psychosomatics addresses the physical and psychological triggers for attacks in Meniere's disease. [More]

AHRF to present free symposium on dizziness and balance disorders

The American Hearing Research Foundation will present a free, day-long educational symposium on dizziness and balance disorders on Saturday, April 6 at the Hilton Suites Chicago/Oakbrook in Oakbrook, Illinois. [More]

Otolaryngology-Head and Neck Surgery publishes new sudden hearing loss guideline

The first national treatment guideline for sudden hearing loss, a frightening condition that sends thousands in the U.S. to the emergency room each year, was published this month in the journal Otolaryngology-Head and Neck Surgery. [More]

Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that researchers presented positive new data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease. [More]

Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced positive data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease. [More]
Research on electrophysiological assessment of hearing in patients with acoustic neuromas

Research on electrophysiological assessment of hearing in patients with acoustic neuromas

Manuel Don, Ph.D., is a principal investigator in the Division of Communication and Auditory Neuroscience at the House Ear Institute. Dr. Don joined the House Ear Institute in 1976 after working as an assistant research auditory physiologist at the University of California, Irvine. [More]

Endolymphatic sac shunt surgery improved hearing loss symptoms in flight attendant

When fluctuating hearing loss, with frequent bouts of nausea and vertigo caused New York flight attendant Patricia Gilbert to miss several work shifts, she sought answers from the medical community. [More]

New ear implant for Meniere’s disease

Meniere’s disease is a disease that affects the inner ear – a region responsible for balance. It affects 1% of Americans and can be quite disabling since it leads to attacks of vertigo. At present medications can not completely cure the condition and surgery is often unsuccessful. [More]

UW Medicine patient receives implantable device for vestibular problems

A University of Washington Medical Center patient on Thursday, Oct. 21, will be the world's first recipient of a device that aims to quell the disabling vertigo associated with Meniere's disease. [More]

Otonomy announces closing of $38.5 million Series B financing

Otonomy, Inc. announced today that it has closed a $38.5 million Series B financing co-led by Novo Ventures and RiverVest Venture Partners, and joined by Domain Associates and TPG Biotech. This financing is incremental to the $10 million Series A closed with Avalon Ventures in June 2010. Avalon also participated in the Series B round. [More]
Study examines impact of microvascular decompression surgery for type 2 diabetes

Study examines impact of microvascular decompression surgery for type 2 diabetes

A team of Allegheny General Hospital (AGH) physicians led by neurosurgical pioneer Peter Jannetta, MD, has made an important new discovery linking the central nervous system to the onset and progression of type 2 diabetes mellitus.Reporting today in the journal Surgical Neurology International, Dr. Jannetta and his colleagues present evidence from a prospective clinical trial that vascular compression of a section of the brain called the medulla oblongata is a factor in some patients with type 2 diabetes and that microvascular decompression surgery (MVD) may be an effective treatment for the condition. [More]
Special issue on new developments in vestibular rehabilitation

Special issue on new developments in vestibular rehabilitation

Rehabilitation is essential for patients with disabling symptoms of dizziness, vertigo, and unsteadiness caused by disorders of the vestibular system. A special issue of The Journal of Neurologic Physical Therapy (JNPT) presents an update on new and emerging vestibular rehabilitation techniques, highlighting the physical therapist's role on the multidisciplinary teams providing patient care and research. [More]

Otonomy completes $10 million Series A financing with Avalon Ventures

Otonomy, Inc. announced today that it has completed a $10 million Series A financing with Avalon Ventures. Proceeds from the financing will be used to support the ongoing clinical trial for OTO-104 in Meniere's disease, initiate IND-enabling studies for OTO-203, and continue early-stage development of a third program. [More]
Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure Ltd., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., has received notice of allowance from the US Patent Office for its two key patent applications covering methods of use and compositions covering the use of betahistine with olanzapine for the mitigation of the serious weight gain associated as a side effect of the antipsychotic drug. [More]

FDA clears Otonomy's IND for clinical trial of OTO-104 in Meniere's disease patients

Otonomy, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of OTO-104 in patients with Meniere's disease, a debilitating disorder of the inner ear affecting balance and hearing. [More]
Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., announced today the execution of a licensing and clinical supply agreement with Farmaceutici Formenti SPA, the Italian Subsidiary of the Grunenthal Group. [More]
Missing molecules lead to deafness

Missing molecules lead to deafness

Researchers have identified tiny molecules that may lead to big breakthroughs in the treatment of hearing loss and deafness. [More]